



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	1	of	3	Attorney Docket Number	47624CIP(71417)
-------	---	----	---	------------------------	-----------------

**Complete if Known**

Application Number	10/696,391-Conf. #6371
Filing Date	October 28, 2003
First Named Inventor	Jeffrey M. Isner
Art Unit	1633
Examiner Name	Q. Nguyen
Attorney Docket Number	47624CIP(71417)

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
/QN	AA**	US 4,296,100			
	AB**	US 5,219,739			
	AC**	<del>US 5,229,496</del>		Duplicate	
	AD**	US 5,332,671			
	AE**	US 5,652,225			
	AF**	US 6,133,231			
	AG**	US-5,612,211		Wilson et al.	
	AH**	US-5,646,043	07-08-1997	Emerson et al.	
	AI**	US-5,941,868		Kaplan et al.	
	AJ**	US-5,980,887	11-09-1999	Isner et al.	
/QN	AK**	US-6,121,246		Isner	
/QN	AL**	US-6,258,787-B1	07-10-2001	Isner	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
/QN	BA**	PCT/EP85/00326				
	BB**	PCT/US96/15813				
	BC**	WO95/22618				
/QN	BD**	WO97/14307				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/QN	CA**	Aharinejad et al. CSF-1 Treatment Promotes Angiogenesis In The Metaphysis Of Osteopetrotic (Toothless, tl) Rats. Bone 16:315-324, 1995.	
	CB**	Aiuti et al. The Chemokine SDF-1 is a Chemoattractant For Human CD34 + Hematopoietic Progenitor Cells and Provides a New Mechanism To Explain the Mobilization of CD34+ Progenitors to Peripheral Blood. J. Exp. Med. 185:111-120, 1997.	
	CC**	Asahara et al. VEGF Contributes to Postnatal Neovascularization by Mobilizing Bone Marrow-derived Endothelial Prognitor Cells. EMBO J. 18:3964-3972, 1999.	
	CD**	Asahara, et al., Blood, 67:842 (1986)	
/QN	CE**	Baffour, et al., "Enhanced Angiogenesis and Growth of Collaterals by In Vivo Administration of Recombinant Basic Fibroblast Growth Factor in a Rabbit Model of Acute Lower Limb Ischemia: Dose-Response Effect Of Basic Fibroblast Growth Factor" J. Vasc. Surg., 16:181-	

Examiner Signature	/Quang Nguyen/	Date Considered	09/18/2007
-----------------------	----------------	--------------------	------------

590482

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/696,391-Conf. #6371
		Filing Date	October 28, 2003
		First Named Inventor	Jeffrey M. Isner
		Art Unit	1633
		Examiner Name	Q. Nguyen
Sheet	2	of	3
		Attorney Docket Number	47624CIP(71417)

		91 (1992).	
/QN	CF**	Baffour, et al., J. Vasc. Surg., 16:181-91 (1992)	
	CG**	Bevilacqua, M. P., Annu. Rev. Immuno., 11:767 (1993)	
	CH**	Brooks, P. C. et al., Science 264:569 (1994)	
	CI**	Civin, C.I. et al., J. Immunol. 133:157 (1984)	
	CJ**	D'Amore, P. A. et al., Annu. Rev. Physiol. 49:453 (1987)	
	CK**	Dang et al., Clin. Canc. Resea. 5:471-474 (1999)	
	CL**	Davis, et al., Hum Gene Ther., 4:151 (1993)	
	CM**	DeVries, C. et al., Science 255:989 (1992)	
	CN**	Felgner, P.L., et al., Nature 349:351-352 (1/24/91)	
	CO**	Ferrara, et al., Biochem. Biophys. Res. Commun., 161:851-855 (1998)	
	CP**	Ferrara, Trends Cardio. Med., 3:244-250 (1993)	
	CQ**	Fina, J. et al., Blood 75: 2417 (1990)	
	CR**	Flamme I. Et al., Development, 116:435 (1992)	
	CS**	Folkman, J. et al., Science 235:442 (1987)	
	CT**	Folkman, N. Engl. J. Med., 285:1182-1186 (1971)	
	CU**	Giodano et al., Nature Medicine 2: No.5 534-539 (Examiner cited)	
	CV**	Grant et al., Proc. Natl. Acad. Sci. 90:1937-1941 (1993) (Examiner cited)	
	CW**	His, W., Abhandl., K. S. Ges. Wiss. Math. Phys. 22, 171 (1900)	
	CX**	Houck, et al., Mol. Endocrinol., 8:1806-1814 (1991)	
	CY**	Jaffe, E. A. et al., J. Clin. Invest. 52:2745 (1973)	
	CZ**	Joukou, et al., J. of Cell. Phys., 173:211-215 (1997)	
	CCA**	Katz, F. et al., Leuk. Res. 9: 191 (1985)	
	CCB**	Kawakami et al., Brain Research Vol. 697:104-111 (1995) (Examiner cited)	
	CCC**	Kessinger A., et al., Blood, 77:211 (1991)	
	CCD**	Klagsbrun, et al., Annu. Rev. Physiol., 53:217-239 (1991)	
	CCE**	Matthews, W. et al., "A Receptor Tyrosine Kinase cDNA Isolated from a Population of Enriched Primitive Hematopoietic Cells and Exhibiting Close Genetic Linkage to c-kit" Proc. Natl. Acad. Sci. USA, 88:9026-9030 (1991).	
	CCF**	Miettinen, M. et al., Am. J. Clin. Pathol., 79:32 (1983)	
	CCG**	Nabel et al., Nature, 362:844(1993)	
	CCH**	Newman, P. J. et al., Science 247:1219 (1990)	
	CCI**	Pepper, M. S. et al., Biochem. Biophys. Res. Comm., 181:902 (1991)	
	CCJ**	Pollerak, et al., J. Biol. Chem., 272:7151-7158 (1997)	
	CKK**	Pu, et al., Circulation, 88:208-215 (1993)	
	CCL**	Pu, et al., J. Surg. Res., 54:575-83 (1993)	
	CCM**	Risau, W. et al., Development 102, 471 (1998)	
	CCN**	Safi et al., J. Mol. Cell. Cerdiol. 29:2311-2325 (1997) (Examiner cited)	
	CCO**	Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1989)	
/QN	CCP**	Sato, Y. et al., Exp. Cell Res. 204:223 (1993)	

Examiner Signature	/Quang Nguyen/	Date Considered	09/18/2007
-----------------------	----------------	--------------------	------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Application Number	10/696,391-Conf. #6371	
			Filing Date	October 28, 2003	
			First Named Inventor	Jeffrey M. Isner	
			Art Unit	1633	
			Examiner Name	Q. Nguyen	
Sheet	3	of	3	Attorney Docket Number	47624CIP(71417)

/QN/	CCQ**	Schaper, W. et al., Circ. Res. 28, 671 (1971)	
	CCR**	Schnurch, H. et al., Development 119, 957 (1993)	
	CCS**	Sheridan, W. et al., Lancet 339:640 (1992)	
	CCT**	Shi et al., "Evidence fo Circulating Bone Marrow-Derived Endothelial Cells," Blood, 92:362-367 (1998).	
	CCU**	Shibuki, K. et al., Nature 358:676 (1991)	
	CCV**	Shpall, E.J. et al., J. Clin. Oncol, 12:28 (1994)	
	CCW**	Simmons, P. J. et al., Blood 80:388 (1992)	
	CCX**	Stratford-Perricaudet L.D., et al. J. Clin. Invest. 90:626-630 (1992)	
	CCY**	Symes et al., Current Opinion in Lipidology, 5:305-312 (1994)	
	CCCA**	Takeshita, et al., Circulation, 90:228-234(1994)	
	CCCB**	Takeshita, S, et al., Laboratory Investigation 74: 1061-1065 (1996)	
	CCCC**	Takeshita, S. et al., "Intramuscular Administration of Vascular Endothelial Growth Factor Induces Dose-Dependent Collateral Artery Augmentation in a Rabbit Model of Chronic Limb Ischemia." Circulation 1994 Nov;90(5 Pt 2):11228-34.	
	CCCD**	Terman, B. I. et al., Biochem. Biophys. Res. Commun. 187:1579 (1992)	
	CCCF**	Tischer, et al., J. Biol. Chem., 806:11947-11954 (1991)	
	CCCG**	Vitadello, M., et al., J. Clin. Invest. 90:626-630 (1992)	
	CCCH**	Weiss, M. et al., J. Clin. Invest., 97:591 (1996)	
	CCCI**	Witzenbichler et al. Chemotactic Properties of Angiopoietin-1 and -2, Ligands for the Endothelial-Specific Receptor Tyrosine Kinase Tie2. J. Biol. Chem 278:18514-18521, 1998.	
	CC CJ**	Wolff, J.A. et al, Science 247:1465-1468 (1990)	
	CCCK**	Yanagisawa-Miwa, et al., "Salvage of Infarcted Myocardium by Angiogenic Action of Basic Fibroblast Growth Factor" Science, 257:1401-1403 (1992).	
/QN/	CCCL**	Yanagisawa-Miwa, et al., Science, 257:1401-1403 (1992)	
	CCCM**	Zellman, F. et al., Circulation (in press) Vol? pages#?	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Applicant's unique citation designation number (optional). \*Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Quang Nguyen/	Date Considered	09/18/2007
-----------------------	----------------	--------------------	------------